MedPath

epoetin alfa

Generic Name
epoetin alfa
Clinical Trials
Related News

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Phase 4
Completed
Conditions
Chemotherapy
Anemia
Cancer
First Posted Date
2007-09-03
Last Posted Date
2010-04-02
Lead Sponsor
Ortho Biotech, Inc.
Target Recruit Count
273
Registration Number
NCT00524407

A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

Phase 4
Terminated
Conditions
Anemia
Chronic Renal Insufficiency
First Posted Date
2007-07-03
Last Posted Date
2011-05-19
Lead Sponsor
Ortho Biotech Products, L.P.
Target Recruit Count
8
Registration Number
NCT00495365

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Phase 4
Terminated
Conditions
Chemotherapy
Anemia
Cancer
First Posted Date
2007-07-03
Last Posted Date
2016-12-20
Lead Sponsor
Ortho Biotech Products, L.P.
Target Recruit Count
25
Registration Number
NCT00495378

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

First Posted Date
2007-03-30
Last Posted Date
2011-12-16
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
111
Registration Number
NCT00454246

Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction

Phase 2
Completed
Conditions
Myocardial Infarction
Interventions
First Posted Date
2007-03-20
Last Posted Date
2009-12-15
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
529
Registration Number
NCT00449488
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Phase 2
Withdrawn
Conditions
Myelodysplastic Syndromes
Anemia
Interventions
First Posted Date
2007-03-13
Last Posted Date
2016-09-20
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Registration Number
NCT00446602

The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease

Phase 3
Completed
Conditions
Anemia
First Posted Date
2007-03-13
Last Posted Date
2011-02-01
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
176
Registration Number
NCT00446576

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Phase 3
Terminated
Conditions
Anemia
Interventions
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
First Posted Date
2007-03-02
Last Posted Date
2016-08-17
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
80
Registration Number
NCT00442416

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

Phase 3
Completed
Conditions
Anemia
Renal Diseases
Interventions
First Posted Date
2007-02-27
Last Posted Date
2014-04-21
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
430
Registration Number
NCT00440466

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

Phase 4
Completed
Conditions
Delayed Graft Function
First Posted Date
2007-01-22
Last Posted Date
2010-05-27
Lead Sponsor
West Penn Allegheny Health System
Target Recruit Count
76
Registration Number
NCT00425126
Locations
🇺🇸

Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy